News & Analysis as of

Artificial Intelligence Initial Public Offering (IPO)

Ropes & Gray LLP

Finding Alpha in Consumer

Ropes & Gray LLP on

As we move through 2025, the phrase “finding alpha” has become the mantra for private equity (PE) investors focused on the consumer sector. Confidence in the sector remains robust, but the narrative has shifted: it is no...more

9Sail

Dear Lawyers: You Don’t Get All Your Business From Referrals, and I Can Prove It

9Sail on

Here’s a reality check that might sting: while 70% of attorneys believe referrals are their greatest channel for new business, only 30% of in-house counsel actually refer their primary law firm to peers. This massive...more

Foley & Lardner LLP

Looking Back and Looking Forward: Where Are We in Venture Capital Mid-2025?

Foley & Lardner LLP on

As we pass the midpoint of 2025, it’s timely to look back at what we saw in the first half and reassess the road ahead.  Were our predictions from the beginning of the year on the mark, or did we get it wrong?  What do we...more

Fenwick & West LLP

H1 2025 Digital Health Recap: Proof in the Pudding

Fenwick & West LLP on

As we pass the midyear mark, 2025 is already shaping up to be one of digital health’s most validating years in recent memory. IPOs are (finally) back. AI-native tools are showing real-world traction with providers. ...more

Woodruff Sawyer

[Ongoing Program] Risk Management for Your Life Sciences Company: Webinar 3 - International Clinical Trials Country Requirements-...

Woodruff Sawyer on

From lab to commercialization: Navigate the evolving risks of life science companies - Life science companies face rapidly evolving risks—from navigating insurance needs during early funding stages to understanding...more

Woodruff Sawyer

[Ongoing Program] Risk Management for Your Life Sciences Company: Webinar 2 - AI In Real Life (Science): Exploring Real World...

Woodruff Sawyer on

From lab to commercialization: Navigate the evolving risks of life science companies - Life science companies face rapidly evolving risks—from navigating insurance needs during early funding stages to understanding...more

Woodruff Sawyer

[Ongoing Program] Risk Management for Your Life Sciences Company: Webinar 1 - Navigating Risk from Lab to IPO: A Guide to...

Woodruff Sawyer on

From lab to commercialization: Navigate the evolving risks of life science companies - Life science companies face rapidly evolving risks—from navigating insurance needs during early funding stages to understanding...more

Cooley LLP

Q1 2025 Venture Financing Report – Interview With Jeff Crowe

Cooley LLP on

Key insights from Jeff Crowe​​​​​​​ - On what differentiates an outstanding venture capital investor: “They have a nose for where technology is going, build deep expertise in their areas of focus, grow their personal...more

WilmerHale

Year in Review: 2024 AI Securities Litigation Trends

WilmerHale on

Claims relating to statements about artificial intelligence (“AI”) have rapidly become a focal point in securities litigation. Similar to the past surge of “greenwashing” claims tied to climate change disclosures, in 2024 we...more

Mintz Edge

The State of the Funding Market for AI Companies: A 2024 - 2025 Outlook

Mintz Edge on

Artificial intelligence (AI) has emerged as an influential technology, driving notable investments across various industries in recent years. In 2024, venture capital (VC) funding for AI companies reached record levels,...more

Akin Gump Strauss Hauer & Feld LLP

2025 Perspectives in Private Equity: AI & Technology

Technology continued to be an industry of particular focus for private equity (PE) through 2024. Blackstone’s $16 billion acquisition of data center platform Airtrunk was the largest deal of Q3 2024, according to Ernst &...more

Akin Gump Strauss Hauer & Feld LLP

Private Equity Deal Activity Review & 2025 Outlook

Despite initial expectations for a strong rebound in M&A activity driven by pent-up demand, private equity managers saw a slower recovery in 2024 than initially expected, with improvement in the latter half of the year....more

A&O Shearman

Southern District Of New York Grants In Part And Denies In Part Motion To Dismiss Claims In Securities Class Action Against...

A&O Shearman on

On January 27, 2025, Judge Jesse M. Furman of the United States District Court for the Southern District of New York partially granted a motion to dismiss a putative securities class action asserting claims under Sections...more

Goodwin

Life Sciences M&A Boom and Other Trends to Watch in 2025

Goodwin on

In mid-January, Goodwin and KPMG brought together innovators, practitioners, regulators, and others for an annual symposium on the future of life sciences and healthcare. This event marked the sixth year that Goodwin...more

Mintz - Venture Capital & Emerging Companies...

MintzTech Connect: All Things Technology — January 2025

As we turn our thoughts to 2025, there is clearly significant enthusiasm in the financial world for a bust-out year in venture capital. Anecdotally, we can readily see that the number of transactions is increasing, and...more

Paul Hastings LLP

Get Ready for the New Outbound Investment Security Program

Paul Hastings LLP on

The final regulations of the Outbound Investment Security Program, issued by the United States Department of the Treasury (the Treasury Department) on October 28, 2024 (the Final Rule), will become effective on January 2,...more

MoFo Tech

Current State of the AI VC Financing Market

MoFo Tech on

While the broader venture capital financing market continues to experience headwinds and turbulence, artificial intelligence (AI) deal activity has been a bright spot for companies and investors, with relatively robust deal...more

Goodwin

Six Hot Trends in Life Sciences for 2025

Goodwin on

The life sciences industry is well positioned for growth in 2025, fueled by strong investor interest and technological advancements, especially in AI. Life sciences venture capital (VC) funding and IPOs have picked up in...more

Cozen O'Connor

Summarizing the SEC’s 2025 Examination Priorities Report, Part 2

Cozen O'Connor on

In the second part of this legal update series, we summarize the key takeaways from the Division of Examinations’ (Division) 2025 priorities report released on October 21, 2024. The Division remains focused on mainstays like...more

Wilson Sonsini Goodrich & Rosati

The Entrepreneurs Report – Q3 2024

In this latest issue of The Entrepreneurs Report, we’ve compiled a range of data on venture, convertible note, and SAFE financing transactions in which the firm was involved during the third quarter of 2024, with the...more

Orrick, Herrington & Sutcliffe LLP

A Conversation with Evercore on the Market Outlook

01 A conversation with Evercore on the market outlook 02 Will there be an alternative path to public? 03 What’s ahead for tech and life sciences IPOs? 04 The Download Quiz: Venture Capital Trends / 01A CONVERSATION WITH...more

Fenwick & West LLP

Securities Law Update - September 2024

Fenwick & West LLP on

Welcome to the latest edition of Fenwick’s Securities Law Update. This issue contains updates and important reminders on...more

Wilson Sonsini Goodrich & Rosati

[Event] Biotech Summit 2024 - October 9th - 10th, Boston, MA

Wilson Sonsini’s inaugural Biotech Summit will address topics of critical importance to Biotech and Biopharmaceutical companies, including early and late-stage venture financing, partnering strategies, current and future AI...more

Fenwick & West LLP

Silicon Alley: 15 Must-Know Facts about NY's Tech Community

Fenwick & West LLP on

As we countdown to NY Tech Week in just 15 days, here are 15 facts about the city's dynamic tech ecosystem....more

Troutman Pepper Locke

Ready for the Biotech Bounce Back in 2024?

Troutman Pepper Locke on

Heading into 2024, expectations for biotech venture capital (VC) and private equity (PE) investments were low following two lackluster years, but as we wrap up Q1, those expectations have been turned on their head after a...more

46 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide